Navigation Links
Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
Date:5/12/2010

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer. Following this approval from the FDA, the Company expects to initiate a Phase 2 clinical trial in this indication in the second half of this year.

The study will be conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine with Gustavo Fernandez, M.D., Assistant Professor of Medicine, as the Principal Investigator, and will include up to 64 patients, male and female, with advanced LHRH-receptor positive urothelial (bladder) cancer. The study will be conducted in two parts; the first one will be a dose-finding part in up to 12 patients and then, the chosen dose will be studied for its effect on progression-free survival.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are very pleased with the FDA's approval and excited about this Phase 2 trial in bladder cancer, since it will be our first with AEZS-108 in the United States, and the first one to include male patients. With this upcoming Phase 2 trial, as well as the current Phase 2 trial in advanced ovarian and endometrial cancer conducted in Europe, for which final results are expected before year-end, AEZS-108 has become a major component of our oncology portfolio."


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Md., Feb. 2, 2012   Spherix Incorporated (NASDAQ: ... for therapy in diabetes, metabolic syndrome and atherosclerosis, and ... supplement, biotechnology and pharmaceutical companies, today announced that it ... of shares of its common stock and warrants to ...
... Switzerland, Feb. 2, 2012 Swisslog and JBT Corporation ... manufacture state-of-the-art AGVs for hospitals. With ... jointly developed and marketed from 2013 onwards. The alliance ... logistics solutions for hospitals. JBT will supply all jointly ...
...   Reportlinker.com announces that a new market research ... U.S. Tissue Engineering Markets ... scope of this research service primarily includes ... wound care and surgery space. Surgery includes ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles 2JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles 3U.S. Tissue Engineering Markets 2U.S. Tissue Engineering Markets 3
(Date:12/10/2014)... here before: you desperately need to sign into your online banking ... to your secret question. What,s your dog,s birthday? Who was your ... a digital infrastructure security company, launches the app that ... usernames, passwords and PINs – 1U TM . 1U ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a new ... this $50 million capital project is part of a larger ... The medical education building will be located in ... to 525@vine in Wake Forest Innovation Quarter. Construction will begin ...
(Date:12/10/2014)... 08, 2014 Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... Market in Japan 2014-2018" report to their offering. ... The integration of biometrics and smart cards for projects ... license is one of the major trends witnessed in ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... from the National Human Genome Research Institute (NHGRI), part ... that mammalian chromosomes have evolved by breaking at specific ... many of the breakage hotspots are also involved in ... July 22 issue of the journal Science, a team ...
... elephants and rhino from extinction could be made more ... as their habitats. , Scientists at the Zoological Society ... London have identified fundamental new approaches to improve the ... journal Science, the largest study of its kind analyses ...
... migration time on Cape Cod again, the time of year ... It's a sign of spring to the fishermen who make ... at the Marine Biological Laboratory (MBL), it triggers an influx ... who return here faithfully every summer to study the squid ...
Cached Biology News:Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations 2Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations 3Size matters: Preventing large mammal extinction 2Gifts from the sea 2Gifts from the sea 3
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
... for fully automated systems for a broad ... configured for applications ranging from compound logistics, ... loop screening, which means it has fully ... picking and follow up studies all at ...
... devices for the fast and reliable clarification/filtration of ... 500 l. They can be used in fixed ... Features: High-flux Polyethersulphonemembrane 0.8 ... volume ( Fast and reproducible performance ...
Biology Products: